71 related articles for article (PubMed ID: 9832306)
21. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
23. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
Benjouad A; Chapuis F; Fenouillet E; Gluckman JC
Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801
[TBL] [Abstract][Full Text] [Related]
24. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
[TBL] [Abstract][Full Text] [Related]
25. The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity.
Wang Y; Pan Q; Ding S; Wang Z; Yu J; Finzi A; Liu SL; Liang C
J Virol; 2017 Apr; 91(7):. PubMed ID: 28100616
[TBL] [Abstract][Full Text] [Related]
26. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
27. Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes.
de Mareuil J; Mabrouk K; Doria E; Moulard M; de Chasteigner S; Oughideni R; van Rietschoten J; Rochat H; De Waard M; Sabatier JM
Antiviral Res; 2002 Jun; 54(3):175-88. PubMed ID: 12062390
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
29. Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.
Verrier FC; Charneau P; Altmeyer R; Laurent S; Borman AM; Girard M
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9326-31. PubMed ID: 9256481
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
32. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
[TBL] [Abstract][Full Text] [Related]
33. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
34. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
[TBL] [Abstract][Full Text] [Related]
35. An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120.
Alam SM; Paleos CA; Liao HX; Scearce R; Robinson J; Haynes BF
AIDS Res Hum Retroviruses; 2004 Aug; 20(8):836-45. PubMed ID: 15320988
[TBL] [Abstract][Full Text] [Related]
36. Conformational properties of the third variable loop of HIV-1AD8 envelope glycoprotein in the liganded conditions.
Takeda S; Takizawa M; Miyauchi K; Urano E; Fujino M; Murakami T; Murakami T; Komano J
Biochem Biophys Res Commun; 2016 Jun; 475(1):113-8. PubMed ID: 27178216
[TBL] [Abstract][Full Text] [Related]
37. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
[TBL] [Abstract][Full Text] [Related]
38. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein.
Shimizu N; Haraguchi Y; Takeuchi Y; Soda Y; Kanbe K; Hoshino H
Virology; 1999 Jul; 259(2):324-33. PubMed ID: 10388657
[TBL] [Abstract][Full Text] [Related]
39. Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.
Alsahafi N; Debbeche O; Sodroski J; Finzi A
PLoS One; 2015; 10(4):e0122111. PubMed ID: 25849367
[TBL] [Abstract][Full Text] [Related]
40. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
J Virol; 2017 May; 91(9):. PubMed ID: 28202756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
